6785.TWO Alar Pharmaceuticals Inc.

Healthcare Drug Manufacturers - Specialty & Generic Taiwan OTC Exchange
73.50 TWD
Close of Nov 5, 2026
71.10 316.68
Market cap
TWD 4.91B
P/E
-
P/B
2.30x
ROE
-1.6%
Dividend yield
0.34%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6785.TWO undervalued?

Graham number

The Graham number of Alar Pharmaceuticals Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alar Pharmaceuticals Inc. fundamental analysis

No fundamental analysis for Alar Pharmaceuticals Inc. yet.

Alar Pharmaceuticals Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alar Pharmaceuticals Inc.

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmac…

Full company profile